Redeye views last Friday’s large block transaction in Physitrack shares as a clear positive for the stock. The sale, amounting to 7.9% of the company, represents the exit of a non-active founder whose steady selling has long acted as a drag on sentiment and liquidity. With this overhang now effectively removed, we believe the market can refocus on Physitrack’s fundamentals and growth prospects rather than the risk of continued supply from legacy shareholders.
LÄS MER
